Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

Dividend investing appears to be a simple strategy on the surface, but in reality, it requires a much deeper analysis.

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Want to buy a good dividend stock and secure a great price in the process? Three stocks that are trading at attractive ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

Lisocabtagene maraleucel (liso‑cel; Breyanzi) is available on the NHS. It is a possible treatment for large B-cell lymphoma (diffuse large B‑cell, high-grade B‑cell, primary mediastinal large B-cell ...

Lisocabtagene maraleucel (liso‑cel; Breyanzi, Bristol-Myers Squibb) is indicated for 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL), high grade B‑cell lymphoma (HGBCL), ...

In the past year, it has secured two key approvals -- one for schizophrenia drug Cobenfy, and another for cancer treatment Breyanzi. Both are potential blockbuster drugs that could generate ...

In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of ...

The regulator highlighted the products by name, including Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) and 2seventy bio-partnered Abecma (idecabtagene vicleucel), Johnson & Johnson ...

Both Yescarta and Kymriah are already on sales in the EU, while Breyanzi is under regulatory review. Meanwhile, Amgen's bispecific antibody Blincyto (blinatumomab) also targets CD19 but is ...